

Lund, March 13, 2023
EQL Pharma AB (publ)
556713-3425

EQL Pharma recruits Carl Lindgren as Chief Business Development Officer

EQL has recruited Carl Lindgren as Chief Business Development Officer (CBDO). Carl replaces Alexander Brising, who was responsible for Business Development and built the company's pipeline since 2016, but now changes position within EQL to Chief Commercial Officer (CCO) with responsibility for the company's sales and marketing.

Carl Lindgren has more than 30 years of experience in the pharmaceutical industry and comes most recently from a role as Vice President M&A/BD at Karo Healthcare (formerly Karo Pharma), which during Carl's time has grown from approx. SEK 350m to approx. 4.5bn in annual turnover. In addition to having been deeply involved in Karo Healthcare's organic growth, Carl has also been responsible for and carried out a number of successful acquisitions.

"EQL is an entrepreneurial company in rapid and profitable growth. I look forward to becoming part of a successful team and to contributing to the continued positive development of the company," says Carl Lindgren.

"With his solid experience and network, Carl is perfect for the role of CBDO in the phase EQL is now entering, with an increased focus on expansion into non-Nordic European markets and profitable synergistic acquisitions." says Axel Schörling, CEO at EQL Pharma. "At the same time, our increasingly large portfolio of products leads to a growing need for commercial efforts to maximize their potential and Alexander, who held similar roles at previous employers, is the right man to lead this".

Carl Lindgren takes up his position as CBDO at EQL in August 2023.

For further information, please contact:

Axel Schörling
CEO & President, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: axel.schorling@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has more than 20 niche generics (i.e. generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2023 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.